{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T04:23:22Z","timestamp":1728620602247},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T00:00:00Z","timestamp":1725235200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Urologie"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00120-024-02421-4","type":"journal-article","created":{"date-parts":[[2024,9,2]],"date-time":"2024-09-02T17:02:00Z","timestamp":1725296520000},"page":"1011-1018","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Das metastasierte\u00a0und\u00a0fortgeschrittene Urothelkarzinom des oberen Harntraktes \u2013 eigene Entit\u00e4t oder doch kleine Schwester des Blasenkarzinoms?","The metastatic and advanced upper tract urothelial carcinoma\u2014a separate entity or bladder cancer\u2019s younger sibling?"],"prefix":"10.1007","volume":"63","author":[{"given":"M.","family":"Haas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Bahlinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Bolenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,2]]},"reference":[{"key":"2421_CR1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel\u00a0RL, Miller\u00a0KD, Wagle\u00a0NS, Jemal\u00a0A (2023) Cancer statistics, 2023. CA Cancer J Clin 73:17\u201348","journal-title":"CA Cancer J Clin"},{"key":"2421_CR2","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00345-010-0594-7","volume":"29","author":"SF Shariat","year":"2011","unstructured":"Shariat\u00a0SF, Favaretto\u00a0RL, Gupta\u00a0A, Fritsche\u00a0HM, Matsumoto\u00a0K, Kassouf\u00a0W et\u00a0al (2011) Gender differences in radical nephroureterectomy for upper tract urothelial carcinoma. World J Urol 29:481\u2013486","journal-title":"World J Urol"},{"key":"2421_CR3","first-page":"1","volume-title":"Upper Tract Urothelial Carcinoma","author":"KGFH-M Dickman","year":"2015","unstructured":"Dickman\u00a0KGFH\u2011M, Grollman\u00a0AP, Thalmann\u00a0GN, Catto\u00a0J (2015) Epidemiology and Risk Factors for Upper Urinary Urothelial Cancers. In: Shariat\u00a0SFXE (Hrsg) Upper Tract Urothelial Carcinoma. Springer, New York, S\u00a01\u201330"},{"key":"2421_CR4","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.eururo.2023.03.013","volume":"84","author":"M Roupr\u00eat","year":"2023","unstructured":"Roupr\u00eat\u00a0M, Seisen\u00a0T, Birtle\u00a0AJ, Capoun\u00a0O, Comp\u00e9rat\u00a0EM, Dominguez-Escrig\u00a0JL et\u00a0al (2023) European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update. Eur Urol 84:49\u201364","journal-title":"Eur Urol"},{"key":"2421_CR5","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/bju.15389","volume":"128","author":"T van Doeveren","year":"2021","unstructured":"van Doeveren\u00a0T, van der Mark\u00a0M, van Leeuwen\u00a0PJ, Boormans\u00a0JL, Aben\u00a0KKH (2021) Rising incidence rates and unaltered survival rates for primary upper urinary tract urothelial carcinoma: a\u00a0Dutch population-based study from 1993 to 2017. BJU Int 128:343\u2013351","journal-title":"BJU Int"},{"key":"2421_CR6","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00345-019-02875-8","volume":"38","author":"F Janisch","year":"2020","unstructured":"Janisch\u00a0F, Shariat\u00a0SF, Baltzer\u00a0P, Fajkovic\u00a0H, Kimura\u00a0S, Iwata\u00a0T et\u00a0al (2020) Diagnostic performance of multidetector computed tomographic (MDCTU) in upper tract urothelial carcinoma (UTUC): a\u00a0systematic review and meta-analysis. World J Urol 38:1165\u20131175","journal-title":"World J Urol"},{"key":"2421_CR7","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1016\/j.juro.2009.12.031","volume":"183","author":"N Takahashi","year":"2010","unstructured":"Takahashi\u00a0N, Glockner\u00a0JF, Hartman\u00a0RP, King\u00a0BF, Leibovich\u00a0BC, Stanley\u00a0DW et\u00a0al (2010) Gadolinium enhanced magnetic resonance urography for upper urinary tract malignancy. J\u00a0Urol 183:1330\u20131365","journal-title":"J Urol"},{"key":"2421_CR8","doi-asserted-by":"crossref","first-page":"790738","DOI":"10.3389\/fsurg.2021.790738","volume":"8","author":"FJ Koll","year":"2021","unstructured":"Koll\u00a0FJ, Meisenzahl\u00a0E, Haller\u00a0B, Maisch\u00a0P, Kirchhoff\u00a0F, Horn\u00a0T et\u00a0al (2021) Evaluation of Pre-operative Biopsy, Surgical Procedures and Oncologic Outcomes in Upper Tract Urothelial Carcinoma (UTUC). Front Surg 8:790738","journal-title":"Front Surg"},{"key":"2421_CR9","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/j.1464-410X.2010.09899.x","volume":"108","author":"J Messer","year":"2011","unstructured":"Messer\u00a0J, Shariat\u00a0SF, Brien\u00a0JC, Herman\u00a0MP, Ng\u00a0CK, Scherr\u00a0DS et\u00a0al (2011) Urinary cytology has a\u00a0poor performance for predicting invasive or high-grade upper-tract urothelial carcinoma. BJU Int 108:701\u2013705","journal-title":"BJU Int"},{"key":"2421_CR10","first-page":"221","volume":"9","author":"Y Zhao","year":"2021","unstructured":"Zhao\u00a0Y, Deng\u00a0FM, Melamed\u00a0J, Huang\u00a0WC, Huang\u00a0H, Ren\u00a0Q (2021) Diagnostic role of urine cytology and ureteroscopic biopsies in detection of high grade upper tract urothelial carcinoma. Am J Clin Exp Urol 9:221\u2013228","journal-title":"Am J Clin Exp Urol"},{"key":"2421_CR11","doi-asserted-by":"crossref","first-page":"810367","DOI":"10.3389\/fonc.2022.810367","volume":"12","author":"JT Klein","year":"2022","unstructured":"Klein\u00a0JT, John\u00a0A, Bohnert\u00a0L, Enderle\u00a0MD, Linzenbold\u00a0W, Bolenz\u00a0C (2022) Improving the Quality of Human Upper Urinary Tract Specimens by Cryobiopsy. Front Oncol 12:810367","journal-title":"Front Oncol"},{"key":"2421_CR12","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.21037\/tau-22-457","volume":"11","author":"E Tomiyama","year":"2022","unstructured":"Tomiyama\u00a0E, Fujita\u00a0K, Hashimoto\u00a0M, Adomi\u00a0S, Kawashima\u00a0A, Minami\u00a0T et\u00a0al (2022) Comparison of molecular profiles of upper tract urothelial carcinoma vs. urinary bladder cancer in the era of targeted therapy: a\u00a0narrative review. Transl Androl Urol 11:1747\u20131761","journal-title":"Transl Androl Urol"},{"key":"2421_CR13","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/MOU.0000000000000936","volume":"32","author":"C Lonati","year":"2022","unstructured":"Lonati\u00a0C, Moschini\u00a0M, Simeone\u00a0C, Spiess\u00a0PE, Necchi\u00a0A (2022) Lynch syndrome in urological practice: diagnosis, therapeutic strategies, and screening for upper tract urothelial carcinoma. Curr Opin Urol 32:40\u201347","journal-title":"Curr Opin Urol"},{"key":"2421_CR14","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.euf.2020.08.001","volume":"7","author":"A Necchi","year":"2021","unstructured":"Necchi\u00a0A, Madison\u00a0R, Pal\u00a0SK, Ross\u00a0JS, Agarwal\u00a0N, Sonpavde\u00a0G et\u00a0al (2021) Comprehensive Genomic Profiling of Upper-tract and Bladder Urothelial Carcinoma. Eur Urol Focus 7:1339\u20131346","journal-title":"Eur Urol Focus"},{"key":"2421_CR15","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin\u00a0DF, Witjes\u00a0JA, Gschwend\u00a0JE, Schenker\u00a0M, Valderrama\u00a0BP, Tomita\u00a0Y et\u00a0al (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N\u00a0Engl J Med 384:2102\u20132114","journal-title":"N Engl J Med"},{"key":"2421_CR16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","volume":"389","author":"AV Balar","year":"2017","unstructured":"Balar\u00a0AV, Galsky\u00a0MD, Rosenberg\u00a0JE, Powles\u00a0T, Petrylak\u00a0DP, Bellmunt\u00a0J et\u00a0al (2017) Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a\u00a0single-arm, multicentre, phase\u00a02\u00a0trial. Lancet 389:67\u201376","journal-title":"Lancet"},{"key":"2421_CR17","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.3390\/curroncol29060312","volume":"29","author":"E Tomiyama","year":"2022","unstructured":"Tomiyama\u00a0E, Fujita\u00a0K, Nakano\u00a0K, Kuwahara\u00a0K, Minami\u00a0T, Kato\u00a0T et\u00a0al (2022) Trop\u20112 in Upper Tract Urothelial Carcinoma. Curr Oncol 29:3911\u20133921","journal-title":"Curr Oncol"},{"key":"2421_CR18","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","volume":"29","author":"N Kl\u00fcmper","year":"2023","unstructured":"Kl\u00fcmper\u00a0N, Ralser\u00a0DJ, Ellinger\u00a0J, Roghmann\u00a0F, Albrecht\u00a0J, Below\u00a0E et\u00a0al (2023) Membranous NECTIN\u20114 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance. Clin Cancer Res 29:1496\u20131505","journal-title":"Clin Cancer Res"},{"key":"2421_CR19","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.3390\/ijms21155390","volume":"21","author":"E Tomiyama","year":"2020","unstructured":"Tomiyama\u00a0E, Fujita\u00a0K, Rodriguez Pena\u00a0MDC, Taheri\u00a0D, Banno\u00a0E, Kato\u00a0T et\u00a0al (2020) Expression of Nectin\u20114 and PD-L1 in Upper Tract Urothelial Carcinoma. Int J Mol Sci 21:5390","journal-title":"Int J Mol Sci"},{"key":"2421_CR20","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00345-016-1871-x","volume":"35","author":"F Soria","year":"2017","unstructured":"Soria\u00a0F, Moschini\u00a0M, Haitel\u00a0A, Wirth\u00a0GJ, Karam\u00a0JA, Wood\u00a0CG et\u00a0al (2017) HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). World J Urol 35:251\u2013259","journal-title":"World J Urol"},{"key":"2421_CR21","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1038\/s41467-019-10873-y","volume":"10","author":"BD Robinson","year":"2019","unstructured":"Robinson\u00a0BD, Vlachostergios\u00a0PJ, Bhinder\u00a0B, Liu\u00a0W, Li\u00a0K, Moss\u00a0TJ et\u00a0al (2019) Upper tract urothelial carcinoma has a\u00a0luminal-papillary T\u2011cell depleted contexture and activated FGFR3 signaling. Nat Commun 10:2977","journal-title":"Nat Commun"},{"key":"2421_CR22","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cncr.24135","volume":"115","author":"V Margulis","year":"2009","unstructured":"Margulis\u00a0V, Shariat\u00a0SF, Matin\u00a0SF, Kamat\u00a0AM, Zigeuner\u00a0R, Kikuchi\u00a0E et\u00a0al (2009) Outcomes of radical nephroureterectomy: a\u00a0series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115:1224\u20131233","journal-title":"Cancer"},{"key":"2421_CR23","doi-asserted-by":"crossref","first-page":"9.e1","DOI":"10.1016\/j.urolonc.2017.09.001","volume":"36","author":"AT Lenis","year":"2018","unstructured":"Lenis\u00a0AT, Donin\u00a0NM, Faiena\u00a0I, Salmasi\u00a0A, Johnson\u00a0DC, Drakaki\u00a0A et\u00a0al (2018) Role of surgical approach on lymph node dissection yield and survival in patients with upper tract urothelial carcinoma. Urol Oncol 36:9.e1\u201399.e","journal-title":"Urol Oncol"},{"key":"2421_CR24","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.eururo.2016.07.014","volume":"70","author":"T Seisen","year":"2016","unstructured":"Seisen\u00a0T, Peyronnet\u00a0B, Dominguez-Escrig\u00a0JL, Bruins\u00a0HM, Yuan\u00a0CY, Babjuk\u00a0M et\u00a0al (2016) Oncologic Outcomes of Kidney-sparing Surgery Versus Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A\u00a0Systematic Review by the EAU Non-muscle Invasive Bladder Cancer Guidelines Panel. Eur Urol 70:1052\u20131068","journal-title":"Eur Urol"},{"key":"2421_CR25","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.eururo.2012.04.052","volume":"65","author":"E Xylinas","year":"2014","unstructured":"Xylinas\u00a0E, Rink\u00a0M, Cha\u00a0EK, Clozel\u00a0T, Lee\u00a0RK, Fajkovic\u00a0H et\u00a0al (2014) Impact of distal ureter management on oncologic outcomes following radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 65:210\u2013217","journal-title":"Eur Urol"},{"key":"2421_CR26","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrurol.2015.24","volume":"12","author":"T Seisen","year":"2015","unstructured":"Seisen\u00a0T, Colin\u00a0P, Roupr\u00eat\u00a0M (2015) Risk-adapted strategy for the kidney-sparing management of upper tract tumours. Nat Rev Urol 12:155\u2013166","journal-title":"Nat Rev Urol"},{"key":"2421_CR27","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2011.05.064","volume":"60","author":"T O\u2019Brien","year":"2011","unstructured":"O\u2019Brien\u00a0T, Ray\u00a0E, Singh\u00a0R, Coker\u00a0B, Beard\u00a0R (2011) Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a\u00a0prospective, multicentre, randomised clinical trial of a\u00a0single postoperative intravesical dose of mitomycin\u00a0C (the ODMIT\u2011C Trial). Eur Urol 60:703\u2013710","journal-title":"Eur Urol"},{"key":"2421_CR28","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1200\/JCO.22.00763","volume":"41","author":"JA Coleman","year":"2023","unstructured":"Coleman\u00a0JA, Yip\u00a0W, Wong\u00a0NC, Sjoberg\u00a0DD, Bochner\u00a0BH, Dalbagni\u00a0G et\u00a0al (2023) Multicenter Phase\u00a0II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma. J\u00a0Clin Oncol 41:1618\u20131625","journal-title":"J Clin Oncol"},{"key":"2421_CR29","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/bju.14719","volume":"124","author":"A Martini","year":"2019","unstructured":"Martini\u00a0A, Daza\u00a0J, Poltiyelova\u00a0E, Gul\u00a0Z, Heard\u00a0JR, Ferket\u00a0BS et\u00a0al (2019) Pathological downstaging as a\u00a0novel endpoint for the development of neoadjuvant chemotherapy for upper tract urothelial carcinoma. BJU Int 124:665\u2013671","journal-title":"BJU Int"},{"key":"2421_CR30","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1002\/cncr.25050","volume":"116","author":"SF Matin","year":"2010","unstructured":"Matin\u00a0SF, Margulis\u00a0V, Kamat\u00a0A, Wood\u00a0CG, Grossman\u00a0HB, Brown\u00a0GA et\u00a0al (2010) Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116:3127\u20133134","journal-title":"Cancer"},{"key":"2421_CR31","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.juro.2017.12.054","volume":"200","author":"RS Liao","year":"2018","unstructured":"Liao\u00a0RS, Gupta\u00a0M, Schwen\u00a0ZR, Patel\u00a0HD, Kates\u00a0M, Johnson\u00a0MH et\u00a0al (2018) Comparison of Pathological Stage in Patients Treated with and without Neoadjuvant Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. J\u00a0Urol 200:68\u201373","journal-title":"J Urol"},{"key":"2421_CR32","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.urology.2019.01.058","volume":"129","author":"X Meng","year":"2019","unstructured":"Meng\u00a0X, Chao\u00a0B, Vijay\u00a0V, Silver\u00a0H, Margolin\u00a0EJ, Balar\u00a0A et\u00a0al (2019) High Response Rates to Neoadjuvant Chemotherapy in High-Grade Upper Tract Urothelial Carcinoma. Urology 129:146\u2013152","journal-title":"Urology"},{"key":"2421_CR33","doi-asserted-by":"crossref","first-page":"e1237","DOI":"10.1016\/j.clgc.2018.08.003","volume":"16","author":"N Almassi","year":"2018","unstructured":"Almassi\u00a0N, Gao\u00a0T, Lee\u00a0B, Stein\u00a0RJ, Haber\u00a0GP, Ornstein\u00a0MC et\u00a0al (2018) Impact of Neoadjuvant Chemotherapy on Pathologic Response in Patients With Upper Tract Urothelial Carcinoma Undergoing Extirpative Surgery. Clin Genitourin Cancer 16:e1237\u2013e1242","journal-title":"Clin Genitourin Cancer"},{"key":"2421_CR34","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/S0140-6736(20)30415-3","volume":"395","author":"A Birtle","year":"2020","unstructured":"Birtle\u00a0A, Johnson\u00a0M, Chester\u00a0J, Jones\u00a0R, Dolling\u00a0D, Bryan\u00a0RT et\u00a0al (2020) Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a\u00a0phase\u00a03, open-label, randomised controlled trial. Lancet 395:1268\u20131277","journal-title":"Lancet"},{"key":"2421_CR35","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1200\/JCO.23.01659","volume":"42","author":"AJ Birtle","year":"2024","unstructured":"Birtle\u00a0AJ, Jones\u00a0R, Chester\u00a0J, Lewis\u00a0R, Biscombe\u00a0K, Johnson\u00a0M et\u00a0al (2024) Improved Disease-Free Survival With Adjuvant Chemotherapy After Nephroureterectomy for Upper Tract Urothelial Cancer: Final Results of the POUT Trial. J\u00a0Clin Oncol 42:1466\u20131471","journal-title":"J Clin Oncol"},{"key":"2421_CR36","doi-asserted-by":"crossref","unstructured":"Dash A, Galsky M, Vickers A, Serio A, Koppie T, Dalbagni G et\u00a0al (2006) Impact of Renal Impairment on Eligibility for Adjuvant Cisplatin-Based Chemotherapy in Patients With Urothelial Carcinoma of the Bladder. Cancer 107:","DOI":"10.1002\/cncr.22031"},{"key":"2421_CR37","doi-asserted-by":"crossref","unstructured":"Galsky MD et\u00a0al (2012) Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann Oncol 23:","DOI":"10.1093\/annonc\/mdr156"},{"key":"2421_CR38","doi-asserted-by":"crossref","unstructured":"Galsky M, Hahn N, Rosenberg J, Sonpavde G, Hutson T, Oh W et\u00a0al (2011) Treatment of patients with metastatic urothelial cancer \u201cunfit\u201d for Cisplatin-based chemotherapy. J\u00a0Clin Oncol 29:","DOI":"10.1200\/JCO.2011.34.8433"},{"key":"2421_CR39","doi-asserted-by":"crossref","unstructured":"Mead G, Russell M, Clark P, Harland S, Harper P, Cowan R et\u00a0al (1998) A\u00a0Randomized Trial Comparing Methotrexate and Vinblastine (MV) With Cisplatin, Methotrexate and Vinblastine (CMV) in Advanced Transitional Cell Carcinoma: Results and a\u00a0Report on Prognostic Factors in a\u00a0Medical Research Council Study. MRC Advanced Bladder Cancer Working Party. Br J Cancer 78:","DOI":"10.1038\/bjc.1998.629"},{"key":"2421_CR40","doi-asserted-by":"crossref","unstructured":"Sternberg C, de Mulder P, Schornagel J, Th\u00e9odore C, Fossa S, van Oosterom A et\u00a0al (2001) Randomized Phase\u00a0III Trial of High-Dose-Intensity Methotrexate, Vinblastine, Doxorubicin, and Cisplatin (MVAC) Chemotherapy and Recombinant Human Granulocyte Colony-Stimulating Factor Versus Classic MVAC in Advanced Urothelial Tract Tumors: European Organization for Research and Treatment of Cancer Protocol No. 30924. J\u00a0Clin Oncol 19:","DOI":"10.1200\/JCO.2001.19.10.2638"},{"key":"2421_CR41","doi-asserted-by":"crossref","unstructured":"Sternberg C, de Mulder P, Schornagel J, Theodore C, Fossa S, van Oosterom A et\u00a0al (2006) Seven Year Update of an EORTC Phase\u00a0III Trial of High-Dose Intensity M\u2011VAC Chemotherapy and G\u2011CSF Versus Classic M\u2011VAC in Advanced Urothelial Tract Tumours. Eur J Cancer 42:","DOI":"10.1016\/j.ejca.2005.08.032"},{"key":"2421_CR42","doi-asserted-by":"crossref","unstructured":"von der Maase H, Sengelov L, Roberts J, Dogliotti L, Oliver T et\u00a0al (2005) Long-term Survival Results of a\u00a0Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer. J\u00a0Clin Oncol 23:","DOI":"10.1200\/JCO.2005.07.757"},{"key":"2421_CR43","doi-asserted-by":"crossref","unstructured":"De Santis M, Bellmunt J, Mead G, Kerst J, Leahy M, Maroto P et\u00a0al (2012) Randomized Phase\u00a0II\/III Trial Assessing Gemcitabine\/Carboplatin and Methotrexate\/Carboplatin\/Vinblastine in Patients With Advanced Urothelial Cancer Who Are Unfit for Cisplatin-Based Chemotherapy: EORTC Study 30986. J\u00a0Clin Oncol 30:","DOI":"10.1200\/JCO.2011.37.3571"},{"key":"2421_CR44","doi-asserted-by":"crossref","first-page":"LBA1","DOI":"10.1200\/JCO.2020.38.18_suppl.LBA1","volume":"38","author":"T Powles","year":"2020","unstructured":"Powles\u00a0T, Park\u00a0SH, Voog\u00a0E, Caserta\u00a0C, Valderrama\u00a0BP, Gurney\u00a0H et\u00a0al (2020) Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase\u00a0III interim analysis. J\u00a0Clin Oncol 38:LBA1\u2013LBA2","journal-title":"J Clin Oncol"},{"key":"2421_CR45","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","volume":"389","author":"MS van der Heijden","year":"2023","unstructured":"van der Heijden\u00a0MS, Sonpavde\u00a0G, Powles\u00a0T, Necchi\u00a0A, Burotto\u00a0M, Schenker\u00a0M et\u00a0al (2023) Nivolumab plus Gemcitabine-Cisplatin in Advanced Urothelial Carcinoma. N\u00a0Engl J Med 389:1778\u20131789","journal-title":"N Engl J Med"},{"key":"2421_CR46","doi-asserted-by":"crossref","unstructured":"Bellmunt J, de Wit R, Vaughn D, Fradet Y, Lee J, Fong L et\u00a0al (2017) Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N\u00a0Engl J Med 376:","DOI":"10.1056\/NEJMoa1613683"},{"key":"2421_CR47","doi-asserted-by":"crossref","unstructured":"Bellmunt J, Fougeray R, Rosenberg J, von der Maase H, Schutz F, Salhi Y et\u00a0al (2013) Long-term Survival Results of a\u00a0Randomized Phase\u00a0III Trial of Vinflunine Plus Best Supportive Care Versus Best Supportive Care Alone in Advanced Urothelial Carcinoma Patients After Failure of Platinum-Based Chemotherapy. Ann Oncol 24:","DOI":"10.1093\/annonc\/mdt007"},{"key":"2421_CR48","doi-asserted-by":"crossref","unstructured":"Bellmunt J, Th\u00e9odore C, Demkov T, Komyakov B, Sengelov L, Daugaard G et\u00a0al (2009) Phase\u00a0III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a\u00a0Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract. J\u00a0Clin Oncol 27:","DOI":"10.1200\/JCO.2008.20.5534"},{"key":"2421_CR49","doi-asserted-by":"crossref","unstructured":"Sonpavde G, Pond G, Choueiri T, Mullane S, Niegisch G, Albers P et\u00a0al (2016) Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma. Eur Urol 69:","DOI":"10.1016\/j.eururo.2015.07.042"},{"key":"2421_CR50","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Valderrama\u00a0BP, Gupta\u00a0S, Bedke\u00a0J, Kikuchi\u00a0E, Hoffman-Censits\u00a0J et\u00a0al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N\u00a0Engl J Med 390:875\u2013888","journal-title":"N Engl J Med"},{"key":"2421_CR51","doi-asserted-by":"crossref","first-page":"TPS497","DOI":"10.1200\/JCO.2019.37.7_suppl.TPS497","volume":"37","author":"DP Petrylak","year":"2019","unstructured":"Petrylak\u00a0DP, Rosenberg\u00a0JE, Duran\u00a0I, Loriot\u00a0Y, Sonpavde\u00a0G, Wu\u00a0C et\u00a0al (2019) EV-301: Phase\u00a0III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la\/mUC). J\u00a0Clin Oncol 37:TPS497\u2013TPS498","journal-title":"J Clin Oncol"},{"key":"2421_CR52","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","volume":"39","author":"ST Tagawa","year":"2021","unstructured":"Tagawa\u00a0ST, Balar\u00a0AV, Petrylak\u00a0DP, Kalebasty\u00a0AR, Loriot\u00a0Y, Fl\u00e9chon\u00a0A et\u00a0al (2021) TROPHY-U-01: A\u00a0Phase\u00a0II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. J\u00a0Clin Oncol 39:2474\u20132485","journal-title":"J Clin Oncol"},{"key":"2421_CR53","doi-asserted-by":"crossref","first-page":"5015","DOI":"10.1200\/JCO.2020.38.15_suppl.5015","volume":"38","author":"AO Siefker-Radtke","year":"2020","unstructured":"Siefker-Radtke\u00a0AO, Necchi\u00a0A, Park\u00a0SH, Garc\u00eda-Donas\u00a0J, Huddart\u00a0RA, Burgess\u00a0EF et\u00a0al (2020) ERDAFITINIB in locally advanced or metastatic urothelial carcinoma (mUC): Long-term outcomes in BLC2001. J\u00a0Clin Oncol 38:5015","journal-title":"J Clin Oncol"},{"key":"2421_CR54","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot\u00a0Y, Matsubara\u00a0N, Park\u00a0SH, Huddart\u00a0RA, Burgess\u00a0EF, Houede\u00a0N et\u00a0al (2023) Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N\u00a0Engl J Med 389:1961\u20131971","journal-title":"N Engl J Med"}],"container-title":["Die Urologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00120-024-02421-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00120-024-02421-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T17:02:54Z","timestamp":1728579774000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00120-024-02421-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,2]]},"references-count":54,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["2421"],"URL":"https:\/\/doi.org\/10.1007\/s00120-024-02421-4","relation":{},"ISSN":["2731-7064","2731-7072"],"issn-type":[{"type":"print","value":"2731-7064"},{"type":"electronic","value":"2731-7072"}],"subject":[],"published":{"date-parts":[[2024,9,2]]},"assertion":[{"value":"24 July 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"M.\u00a0Haas, V.\u00a0Bahlinger, M.\u00a0Burger, C.\u00a0Bolenz und Y.\u00a0Ma geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}